Last reviewed · How we verify
Cordran (fludroxycortide)
At a glance
| Generic name | fludroxycortide |
|---|---|
| Sponsor | Aqua Pharms |
| Drug class | Corticosteroid [EPC] |
| Target | Glucocorticoid receptor |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1963 |
Approved indications
- Atopic dermatitis
- Contact dermatitis
- Discoid lupus erythematosus
- Eruption of skin
- Granuloma annulare
- Lichen simplex chronicus
- Plaque psoriasis
- Primary cutaneous T-cell lymphoma
- Pruritus ani
- Pruritus of genital organs
- Scalp psoriasis
- Seborrheic dermatitis
Common side effects
- Skin atrophy
- Skin striae
- Hypersensitivity
- Contact dermatitis
- Skin discoloration
Key clinical trials
- Steroid Impregnated Tape in the Treatment of Over-granulating Peritoneal Dialysis Exit Sites (PHASE3)
- Haelan and Nutrition in Cancer Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cordran CI brief — competitive landscape report
- Cordran updates RSS · CI watch RSS
- Aqua Pharms portfolio CI